glp-1 in development What is the pipeline for future medications for obesity? Frontiers | GLP-1R in diabetes

However, data is extremely limited

[DOI] [PMC free article] [PubMed] [Google Scholar] 37.Farrs J., Pujol A., Coma M., Ruiz J.L., Naval J., Mas J.M., Molins A., Fondevila J., Aloy P

doi: 10.1056/NEJMoa2032183 20 FoxCKAuerbachPBarrientos-PrezMGiesIHalePMMarcusCet al

With NEX, pharma companies, metabolic health clinics, and prescribing networks can launch branded GLP-1 companion apps in months and integrate multiple biosensors with ease, while generating real-world evidence to strengthen reimbursement strategies and scale patient engagement globally

While thirst is not a direct adverse effect of semaglutide according to the UK SmPC, individual responses to medication vary, and patients should monitor their symptoms carefully